Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.
You may also be interested in...
France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.
Junshi and Coherus's PD-1 was already gaining attention for a particularly difficult cancer type even before the meeting, but new data add to its luster ahead of a potential US approval.
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.